| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
In the last three months, 4 analysts have published ratings on GE HealthCare Techs (NASDAQ:GEHC), offering a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 0 | 3 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 2 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $78.5, a high estimate of $89.00, and a low estimate of $73.00. Highlighting a 3.09% decrease, the current average has fallen from the previous average price target of $81.00.
A comprehensive examination of how financial experts perceive GE HealthCare Techs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Patrick Wood | Morgan Stanley | Lowers | Equal-Weight | $74.00 | $78.00 |
| Joanne Wuensch | Citigroup | Raises | Buy | $89.00 | $86.00 |
| Patrick Wood | Morgan Stanley | Lowers | Equal-Weight | $78.00 | $86.00 |
| Graham Doyle | UBS | Lowers | Neutral | $73.00 | $74.00 |
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of GE HealthCare Techs's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on GE HealthCare Techs analyst ratings.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining GE HealthCare Techs's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2.73% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: GE HealthCare Techs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 11.81% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): GE HealthCare Techs's ROE excels beyond industry benchmarks, reaching 6.4%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): GE HealthCare Techs's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.69%, the company showcases efficient use of assets and strong financial health.
Debt Management: GE HealthCare Techs's debt-to-equity ratio is below the industry average at 1.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: GEHC
